Cases & Deals

Sequoia China invests in HiFiBiO Therapeutics

Clients Sequoia China

Jones Day represented Sequoia China in connection with its purchase of Series B Convertible Preferred Stock in a private placement by HiFiBiO Therapeutics, a world leader in the discovery of therapeutic antibodies through single-B-cell screening and analysis.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.